Diagnosis and treatment of human African trypanosomiasis

Abstract

Abstract:

Human African trypanosomiasis (HAT) is a neglected tropical disease. The diagnosis and treatment of HAT is quite complicated. With the large-scale migration of populations and the globle economic activity, the imported cases of HAT are increasing these years. Therefore, the training of professionals and technicians on the related knowledge and technology is particularly important. In this paper, the diagnosis and treatment schemes of HAT are systemically summarized for the reference of clinicians and laboratory technicians.

Key words: Human African trypanosomiasis, Diagnosis, Treatment

CLC Number:

R531.9

Qin LIU, Mu-xin CHEN, Yuan-yuan LI, Yi ZHANG, Shi-zhu LI, Jia-xu CHEN, Xiao-nong ZHOU. Diagnosis and treatment of human African trypanosomiasis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2018, 36(5): 435-442.

Figures/Tables 4

References 61

[1]	Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee[J]. World Health Organ Tech Rep Ser, 2013, 881: Ⅰ-Ⅵ, 1-114.
[2]	甘绍伯. 非洲锥虫病[J]. 中国热带医学, 2009, 9(6): 983-984.
[3]	Franco JR, Simarro PP, Diarra A, et al. Epidemiology of human African trypanosomiasis[J]. Clin Epidemiol, 2014, 6: 257-275.
[4]	Büscher P, Cecchi G, Jamonneau V, et al. Human African trypanosomiasis[J]. Lancet, 2017, 390(10110): 2397-2409.
[5]	Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of human African trypanosomiasis: Update to 2014[J]. PLoS Negl Trop Dis, 2017, 11(5): e0005585.
[6]	Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries(2000-2010)[J]. J Travel Med, 2012, 19(1): 44-53.
[7]	Wang X, Ruan Q, Xu B, et al. Human African trypanosomiasis in emigrant returning to China from Gabon, 2017[J]. Emerging Infect Dis, 2018, 24(2): 400-404.
[8]	Chappuis F, Pittet A, Bovier PA, et al. Field evaluation of the CATT/Trypanosoma brucei gambiense on blood-impregnated filter papers for diagnosis of human African trypanosomiasis in southern Sudan[J]. Trop Med Int Health, 2002, 7(11): 942-948.
[9]	Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study[J]. Lancet Glob Health, 2014, 2(6): e359-e363.
[10]	Lumbala C, Bessell PR, Lutumba P, et al. Performance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo[J]. PLoS One, 2017, 12(7): e0180555.
[11]	Bisser S, Lumbala C, Nguertoum E, et al. Sensitivity and specificity of a prototype rapid diagnostic test for the detection of Trypanosoma brucei gambiense infection: a multi-centric prospective study[J]. PLoS Negl Trop Dis, 2016, 10(4): e0004608.
[12]	Camara O, Camara M, Lejon V, et al. Immune trypanolysis test with blood spotted on filter paper for epidemiological surveillance of sleeping sickness[J]. Trop Med Int Health, 2014, 19(7): 828-831.
[13]	Kagbadouno MS, Camara M, Rouamba J, et al. Epidemiology of sleeping sickness in Boffa (Guinea): where are the trypanosomes[J]. PLoS Negl Trop Dis, 2012, 6(12): e1949.
[14]	Reijer PJ, Beckers EJ.Rhodesiense trypanosomiasis, complicated by ascites. A case report[J]. Trop Geogr Med, 1982, 34(3): 274-276.
[15]	Pyana PP, Ngay Lukusa I, Mumba Ngoyi D, et al. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice[J]. PLoS Negl Trop Dis, 2011, 5(4): e1025.
[16]	Mumba Ngoyi D, Menten J, Pyana PP, et al. Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques[J]. Trop Med Int Health, 2013, 18(6): 778-782.
[17]	Camara M, Camara O, Ilboudo H, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test[J]. Trop Med Int Health, 2010, 15(7): 796-799.
[18]	Büscher P, Mumba Ngoyi D, Kaboré J, et al. Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging[J]. PLoS Negl Trop Dis, 2009, 3(11): e471.
[19]	Miézan TW, Meda HA, Doua F, et al. Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes[J]. Trans R Soc Trop Med Hyg, 2000, 94(3): 293.
[20]	Büscher P, Deborggraeve S.How can molecular diagnostics contribute to the elimination of human African trypanosomiasis[J]. Expert Rev Mol Diagn, 2015, 15(5): 607-615.
[21]	Deborggraeve S, Lejon V, Ekangu RA, et al. Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study[J]. PLoS Negl Trop Dis, 2011, 5(2): e972.
[22]	Kirchhoff LV.Use of a PCR assay for diagnosing African trypanosomiasis of the CNS: a case report[J]. Cent Afr J Med, 1998, 44(5): 134-136.
[23]	Deborggraeve S, Büscher P.Molecular diagnostics for sleeping sickness: what is the benefit for the patient[J]. Lancet Infect Dis, 2010, 10(6): 433-439.
[24]	孙懿, 黄韦华, 牛紫光, 等. 1例输入性非洲锥虫病的病原学鉴定[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(4): 350-354.
[25]	Gibson W, Backhouse T, Griffiths A.The human serum resistance associated gene is ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout East Africa[J]. Infect Genet Evol, 2002, 1(3): 207-214.
[26]	Campillo N, Carrington M.The origin of the serum resistance associated (SRA) gene and a model of the structure of the SRA polypeptide from Trypanosoma brucei rhodesiense[J]. Mol Biochem Parasitol, 2003, 127(1): 79-84.
[27]	Radwanska M, Magnus E, Claes F, et al. Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense[J]. Am J Tropl Med Hyg, 2002, 67(3): 289-295.
[28]	Bonnet J, Boudot C, Courtioux B.Overview of the diagnostic methods used in the field for human African trypanosomiasis: what could change in the next years?[J]. BioMed Res Int, 2015, 2015: 583262.
[29]	万学红, 卢雪峰. 诊断学[M]. 北京: 人民卫生出版社, 2013: 327.
[30]	Barrett MP, Vincent IM, Burchmore RJ, et al. Drug resistance in human African trypanosomiasis[J]. Future Microbiol, 2011, 6(9): 1037-1047.
[31]	Tiberti N, Matovu E, Hainard A, et al. New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients[J]. Clin Transl Med, 2013, 2(1): 1.
[32]	Amin DN, Ngoyi DM, Nhkwachi GM, et al. Identification of stage biomarkers for human African trypanosomiasis[J]. Am J Trop Med Hyg, 2010, 82(6): 983-990.
[33]	Njamnshi AK, Gettinby G, Kennedy PGE.The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question[J]. Trans R Soc Trop Med Hyg, 2017, 111(5): 199-203.
[34]	Pohlig G, Bernhard SC, Blum J, et al. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial[J]. PLoS Negl Trop Dis, 2016, 10(2): e0004363.
[35]	Babokhov P, Sanyaolu AO, Oyibo WA, et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis[J]. Pathog Glob Health, 2013, 107(5): 242-252.
[36]	Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase Ⅲ, non-inferiority trial[J]. Lancet, 2009, 374(9683): 56-64.
[37]	Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis[J]. Cochrane Database Syst Rev, 2013(6): CD006201.
[38]	Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda[J]. PLoS Clin Trials, 2006, 1(8): e39.
[39]	Franco JR, Simarro PP, Diarra A, et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis[J]. Res Rep Trop Med, 2012, 3: 93-101.
[40]	Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness[J]. PLoS Negl Trop Dis, 2012, 6(11): e1920.
[41]	Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study[J]. BMJ, 2008, 336(7646): 705-708.
[42]	Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis[J]. Clin Infect Dis, 2005, 41(5): 748-751.
[43]	Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment oflate-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II)[J]. J Infect Dis, 2005, 191(11): 1922-1931.
[44]	Reto B, Johannes B, Francois C, et al. Human African trypanosomiasis[J]. Handb Clin Neurol, 2010, 114: 169-181.
[45]	Kibona SN, Matemba L, Kaboya JS, et al. Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania[J]. Trop Med Int Health, 2006, 11(2): 144-155.
[46]	Pyana PP, Sere M, Kaboré J, et al. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo[J]. Infect Genet Evol, 2015, 30: 128-133.
[47]	Baker N, de Koning HP, M ser P, et al. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story[J]. Trends Parasitol, 2013, 29(3): 110-118.
[48]	Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward[J]. PLoS Negl Trop Dis, 2011, 5(2): e1007.
[49]	Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo[J]. Bull World Health Organ, 2006, 84(10): 783-791.
[50]	Robays J, Nyamowala G, Sese C, et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo[J]. Emerging Infect Dis, 2008, 14(6): 966-967.
[51]	杜金, 朱明彦. 人类非洲锥虫病的治疗研究进展[J]. 现代生物医学进展, 2015, 15(6): 1154-1159.
[52]	Field MC, Horn D, Fairlamb AH, et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need[J]. Nat Rev Microbiol, 2017, 15(7): 447.
[53]	Patrick DA, Gillespie JR, McQueen J, et al. Urea derivatives of 2-Aryl-benzothiazol-5-amines: a new class of potential drugs for human African trypanosomiasis[J]. J Med Chem, 2017, 60(3): 957-971.
[54]	Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies[J]. Clin Pharmacokinet, 2014, 53(6): 565-580.
[55]	Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis[J]. PLoS Negl Trop Dis, 2011, 5(6): e1151.
[56]	Carrillo AK, Guiguemde WA, Guy RK.Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)[J]. Bioorg Med Chem, 2015,23(16): 5151-5155.
[57]	Priotto G, Chappuis F, Bastard M, et al. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis[J]. PLoS Negl Trop Dis, 2012, 6(6): e1662.
[58]	Lejon V, Buscher P.Stage determination and follow-up in sleeping sickness[J]. Med Trop (Mars), 2001, 61(4/5): 355-360.
[59]	Lejon V, Büscher P.Review article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up[J]. Trop Med Int Health, 2005, 10(5): 395-403.
[60]	Mumba Ngoyi D, Lejon V, Pyana P, et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness[J]. J Infect Dis, 2010, 201(3): 453-463.
[61]	Liu Q, Chen XL, Chen MX, et al. Trypanosoma brucei rhodesiense infection in a Chinese traveler returning from the Serengeti National Park in Tanzania[J]. Infect Dis Poverty, 2018, 7(1): 50.

类型	g-HAT	r-HAT
病原体	布氏锥虫冈比亚亚种	布氏锥虫罗德西亚种
分布	非洲中部和西部	非洲东部和南部
急性或慢性	通常为慢性	通常为急性
病例比例	95%以上的病例	5%以下的病例
主要传播媒介的种类	主要是Nemorhina 亚属的采采蝇	主要是Glossina亚属的采采蝇
保藏宿主	主要是人类	人畜共患病,多种野生动物及家畜均为保藏宿主
虫血症水平	很低（通常<100个锥虫/ml血）	相对较高,病原学检测较易
病程	进入第二阶段平均需要300~500 d	进入第二阶段平均需要3周~2个月
第一阶段一线治疗药物	戊烷脒	苏拉明
第二阶段一线治疗药物	硝夫替莫和依氟鸟氨酸联合用药（NECT）	美拉胂醇
是否有血清学检测	有	否
分子检测特异性基因	特异性的单拷贝布氏锥虫冈比亚亚种的可变抗原（TgSGP）基因	特异性的单拷贝的血清抗性相关（SRA）基因

镜检	白细胞计数
镜检	1~5个/μl血样	≥ 6个/μl血样
锥虫阴性	血淋巴期	脑膜脑炎期
	第一阶段	第二阶段
锥虫阳性	脑膜脑炎期	脑膜脑炎期
	第二阶段	第二阶段

g-HAT
阶段	第一线治疗药物		备选治疗药物		第一线治疗药物		备选治疗药物
阶段	药物名称	给药方案	药物名称	给药方案	药物名称	给药方案	药物名称	给药方案
第一阶段	戊烷脒	4 mg/(kg·d)肌内注射或是稀释于生理盐水在2 h内静脉注射,连续7 d			苏拉明	第1天4~5 mg/kg静脉注射（实验性给药）,然后20 mg/kg静脉注射,每周1次,连续5周（每次最大剂量不超过1 g,时间分别为第3、10、17、24和31天）	戊烷脒（在没有苏拉明的情况下使用,可延缓病情发展）	4 mg/(kg·d)肌内注射或是稀释于生理盐水在2 h内静注,连续7 d
第二阶段	硝夫替莫和依氟鸟氨酸联合用药（NECT）	硝夫替莫15 mg/(kg·d)分3次口服,连续10 d;依氟鸟氨酸400 mg/(kg·d),分两次静脉注射,每次溶于250 ml生理盐水,在2 h内注射完,连续7 d^a	依氟鸟氨酸（第二线药物）;美拉胂醇（第三线药物,只在复发时使用）	依氟鸟氨酸,剂量400 mg/(kg·d),分4次静脉注射,每次溶于100 ml生理盐水,在2 h注射完,连续14 d;美拉胂醇静脉注射,剂量2.2 mg/(kg·d),连续10 d	美拉胂醇	2.2 mg/(kg·d),静脉注射,连续10 d